Orbit Genomics is proud to attend the graduation of the CancerX Accelerator’s inaugural cohort. We were selected from over 100 startup applicants to participate in this year’s program which included months of mentorship, hands-on learning at the Moffit Cancer Center, and many professional sessions with Champions. We look forward to continue strengthening the relationships with our esteemed champions – Advocate Health (Atrium Health) and Moffitt Cancer Center.
Because of the incredible contributions between Startups and Champions in the Accelerator program, the inaugural class will generate and scale ideas that have the potential to save lives and improve the experience of cancer patients and their caregivers.
We congratulate the other 15 extraordinary startup companies in this year’s cohort; and thank the CancerX Members as well as the Program Champions and Mentors for all the hard work, support, and collaboration that went in to this opportunity.
About CancerX:
- CancerX is a public-private partnership (PPP) announced by The White House as a national accelerator to boost innovation in the fight against cancer as part of the reignited Cancer Moonshot.
- CancerX and its more than 150 members are working to achieve national goals for the Cancer Moonshot of reducing the death rate from cancer by at least 50 percent over the next 25 years and improving the experience of people and their families living with and surviving cancer.
About CancerX Accelerator
- CancerX Accelerator is the first-ever digital innovation accelerator and the only one focused on digital innovation in targeting improvement to cancer care.
- The program unites innovators with consumers to break silos in how solutions are developed, deployed, and scaled with end-users.
- The 2024 cohort of startups include: The Blue Box, C the Signs, Cancer Insights, Curiva, EnteroTrack, Gesund.ai, Gray, Lind AI, Mika, Navya, Oatmeal Health, Orbit Genomics, Realyze Intelligence, Reimagine Care, SurvivorPlan, XanthosHealth
- The judging for the inaugural class of the CancerX Accelerator, in partnership with MassChallenge, was led by Moffitt Cancer Center alongside CancerX Accelerator Champions Atrium, AstraZeneca, AWS, Debiopharm, Dell Technologies, Intel, Oncology Ventures, Reveal HealthTech, and UC Davis Health , CancerX members and mentors, and CancerX co-host DiMe, with insight and observation by their federal partners.
Sign up to receive information about CancerX news.